Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, with its lead antifungal candidate, rezafungin, and with antiviral therapies from Cidara’s proprietary Cloudbreak® platform targeting influenza and other viral diseases. Cidara is headquartered in San Diego, California, and is built around the core values of collaboration, integrity, accountability, urgency, and courage.